Physical Inactivity and Appetite Regulation (NCT06240208) | Clinical Trial Compass
RecruitingNot Applicable
Physical Inactivity and Appetite Regulation
Denmark40 participantsStarted 2024-03-01
Plain-language summary
The goal of this parallel-group, two-arm, assessor-blinded, randomised clinical trial is to investigate the effects of reducing physical activity on food intake and satiety in physically active and healthy males, 40-55 years of age.
The main questions it aims to answer are:
* Does physical inactivity affect GLP-1 stimulated food intake?
* Does physical inactivity affect food preferences, satiety and other mechanisms supporting appetite regulation?
Participants will be randomised (1:1) to two weeks of either no intervention (control group) or inactivity. Inactivity will be implemented as cessation of active commuting and all other structured exercise. Furthermore, steps will be reduced to a maximum of 1500 steps/day.
Researchers will compare the inactivity group to the control group to see if physical inactivity impairs appetite regulation.
Who can participate
Age range40 Years ā 55 Years
SexMALE
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion criteria
ā. Male
ā. Age ā„ 40 years and ā¤ 55 years
ā. Body mass index (BMI) \> 20 and \< 25 kg/m2
ā. Physical activity level should as a minimum include: Active commuting by biking a minimum of 10 km, four days per week or an equivalent amount of other physical activity four days per week.
ā. Healthy (based on self-reporting, pre-study medical examination and biochemical screening)
ā. Can adhere to two weeks of inactivity (refrain from running, cycling and all other exercise while reducing steps to max. 1500 pr. day)
ā. Caucasian
ā. No change in body weight \> 5 kg within the last 6 months
Exclusion criteria
ā. Clinical or biochemical signs of disease
ā. HbA1c \> 39 mmol/mol
What they're measuring
1
The change in food intake at an ad libitum meal during GLP-1 infusion
Timeframe: From baseline (week 0) to follow-up (week 2).